GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Procyon Corp (OTCPK:PCYN) » Definitions » Cash-to-Debt

PCYN (Procyon) Cash-to-Debt : 2.84 (As of Jun. 2024)


View and export this data going back to . Start your Free Trial

What is Procyon Cash-to-Debt?

Cash to Debt Ratio measures the financial strength of a company. It is calculated as a company's cash, cash equivalents, and marketable securities divide by its debt. Procyon's cash to debt ratio for the quarter that ended in Jun. 2024 was 2.84.

If Cash to Debt ratio is greater than 1, the company can pay off its debt using the cash in hand. Here we can see, Procyon could pay off its debt using the cash in hand for the quarter that ended in Jun. 2024.

The historical rank and industry rank for Procyon's Cash-to-Debt or its related term are showing as below:

PCYN' s Cash-to-Debt Range Over the Past 10 Years
Min: 1.56   Med: 3.46   Max: No Debt
Current: 2.84

During the past 13 years, Procyon's highest Cash to Debt Ratio was No Debt. The lowest was 1.56. And the median was 3.46.

PCYN's Cash-to-Debt is not ranked
in the Drug Manufacturers industry.
Industry Median: 1.02 vs PCYN: 2.84

Procyon Cash-to-Debt Historical Data

The historical data trend for Procyon's Cash-to-Debt can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Note: An indication of "No Debt" does not necessarily mean that the company has no debt obligations; it could be due to missing data in the quarterly or annual report. Use caution when interpreting this information.

* Premium members only.

Procyon Cash-to-Debt Chart

Procyon Annual Data
Trend Jun15 Jun16 Jun17 Jun18 Jun19 Jun20 Jun21 Jun22 Jun23 Jun24
Cash-to-Debt
Get a 7-Day Free Trial Premium Member Only Premium Member Only 4.09 1.87 1.59 2.05 2.84

Procyon Quarterly Data
Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24
Cash-to-Debt Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 2.05 2.15 2.06 2.48 2.84

Competitive Comparison of Procyon's Cash-to-Debt

For the Drug Manufacturers - Specialty & Generic subindustry, Procyon's Cash-to-Debt, along with its competitors' market caps and Cash-to-Debt data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Procyon's Cash-to-Debt Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Procyon's Cash-to-Debt distribution charts can be found below:

* The bar in red indicates where Procyon's Cash-to-Debt falls into.


;
;

Procyon Cash-to-Debt Calculation

This is the ratio of a company's Cash, Cash Equivalents, Marketable Securities to its debt. The debt includes the Short-Term Debt & Capital Lease Obligation and Long-Term Debt & Capital Lease Obligation. This ratio measures the financial strength of a company. This ratio is updated quarterly.

Procyon's Cash to Debt Ratio for the fiscal year that ended in Jun. 2024 is calculated as:

Procyon's Cash to Debt Ratio for the quarter that ended in Jun. 2024 is calculated as:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Procyon  (OTCPK:PCYN) Cash-to-Debt Explanation

If Cash to Debt ratio is greater than 1, the company can pay off its debt using the cash in hand. If it is smaller than 1, it means the company has more debt than the cash in hands. In this case, it is important to look the the company's Interest Coverage. Ben Graham requires that a company must have an Interest Coverage of at least 5.


Procyon Cash-to-Debt Related Terms

Thank you for viewing the detailed overview of Procyon's Cash-to-Debt provided by GuruFocus.com. Please click on the following links to see related term pages.


Procyon Business Description

Traded in Other Exchanges
N/A
Address
164 Douglas Road, Oldsmar, FL, USA, 34677
Procyon Corp is a United-based company, through its subsidiary, it is engaged in developing and marketing proprietary medical products used to treat pressure ulcers, stasis ulcers, wounds, dermatitis, inflammation, and other skin problems. Its wound care products are sold through distributors to institutional customers such as hospitals, wound care clinics, skilled nursing facilities, home health agencies, and physicians and other healthcare practitioners. The firm's product lines are AMERX, AMERIGEL, and HELIX3 Bioactive Collagen. The skin and wound care products are marketed under the trademark AMERIGEL which contains the proprietary ingredient OAKIN which promotes wound healing and healthy skin. The corporation markets its products in the United States.
Executives
Foundation Speer 10 percent owner 2535 SUCCESS DRIVE, ODESSA FL 33556
Suggs Fred Wilson Jr director 60 FOREST LANE, GREENVILLE SC 29605
Steven Mccomas director 800 LASTAHOUSE DRIVE, VIDALIA GA 30474
Monica Mccullough director 1095 55TH TERR SO, SAINT PETERSBURG FL 33705
Joseph Raymond Treshler director PO BOX 5719, CLEARWATER FL 33758
George Otis Borak officer: Vice President 3300 COVE CAY DR, UNIT 7D, CLEARWATER FL 33760
Lynnda L Speer 10 percent owner 2535 SUCCESS DRIVE, ODESSA FL 33556
Richard M. Speer 10 percent owner 104 WOODMONT BOULEVARD, SUITE 415, NASHVILLE TN 37205
Speer Roy M Foundation 10 percent owner 2535 SUCCESS DRIVE, ODESSA FL 33556
Paul Edward Kudelko director 28 WINSTON DR, BELLEAIR FL 33756
Justice Wolfe Anderson director, officer: VP-Sales and Marketing 1300 S HIGHLAND AVE, CLEARWATER FL 33756
Regina Wolfe Anderson director 1300 S HIGHLAND AVE, CLEARWATER FL 33756
Jeffrey S Slowgrove director C/O INFORMATION MANAGEMENT RESOURCES INC, 26750 US HIGHWAY N #500, CLEARWATER FL 34621
John C Anderson Trust 10 percent owner 440 S GULFVIEW BLVD, APT 1702N, CLEARWATER FL 33767
Michael Timothy Foley director 2284 KINGS POINT DRIVE, LARGO FL 33774

Procyon Headlines

No Headlines